Yantai Dongcheng Biochemicals (002675.SZ): The application for the market approval of Fluorine [18F] Sireotide Injection has been accepted.

Yantai Dongcheng Biochemicals (002675.SZ) announced that its holding subsidiary, Yantai Lanna Cheng Biotechnology Co., Ltd. ("Lanna Cheng"), has received the "Acceptance Notice" issued by the National Medical Products Administration for the market approval application of Lanna Cheng's investigational drug Fluorine [18F] Suriptide Injection. Fluorine [18F] Suriptide Injection is a targeted radioactive in vivo diagnostic drug for PSMA, suitable for positron emission tomography (PET) imaging of prostate cancer patients with positive prostate-specific membrane antigen (PSMA) lesions, including: (1) patients with prostate cancer suspected of having metastases and are planning to undergo initial curative treatment; (2) patients with elevated serum prostate specific antigen (PSA) levels suspected of having biochemical recurrence.